Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.

ABSTRACT:

Background

Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients.

Objectives

We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI.

Methods

In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19

SUBMITTER: van Leeuwen LPM 

PROVIDER: S-EPMC8996444 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature